PROVECTUS BIOPHARMACEUTICALS, INC.·4

Jun 5, 2:58 PM ET

Pershing Edward 4

4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Jun 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Provectus (PVCT) CEO Pershing Converts Note to 9,436 Preferred

What Happened

  • Pershing (CEO and director) converted a 2025 unsecured convertible promissory note into 9,436 shares of Series D‑1 Convertible Preferred Stock on June 5, 2026. The Form 4 reports the derivative acquisition at $0.00 (code M = exercise/conversion of derivative). No open‑market purchase or sale of common stock is reported.

Key Details

  • Transaction date: 2026-06-05; Form 4 filed same day (timely).
  • Reported transaction: Exercise/conversion of a derivative (code M) — 9,436 Series D‑1 preferred shares acquired at $0.00 (derivative).
  • Conversion mechanics (footnotes): each Series D‑1 preferred is convertible into 10 shares of common stock (F1), so the preferred shares represent up to 94,360 common-share equivalents if and when converted.
  • The 2025 Note conversion: the 8% unsecured convertible promissory note from the issuer's 2025 financing automatically converted into Series D‑1 preferred on the conversion date; the conversion terms referenced a $2.862 per‑share price used to determine the preferred share count (F3, F4).
  • Shares owned after the transaction: not disclosed in the provided Form 4.
  • No immediate sale of common shares is reported.

Context

  • This is a conversion of debt into preferred stock rather than a cash purchase or open‑market trade. The preferred shares may convert into common stock (automatically on Dec 31, 2028 unless earlier converted, per the Certificate of Designation), so the economic exposure to common shares could increase in the future if conversion occurs. The filing shows no cash changing hands on the Form 4 (reported $0.00) even though the conversion share count was determined under the note’s conversion price.

Insider Transaction Report

Form 4
Period: 2026-06-05
Pershing Edward
DirectorCEO10% Owner
Transactions
  • Exercise/Conversion

    8% Unsecured Convertible Promissory Note

    [F3][F4]
    2026-06-05
    Exercise: $2.86From: 2025-06-05Exp: 2026-06-05Series D-1 Convertible Preferred Stock (9,436 underlying)
  • Exercise/Conversion

    Series D-1 Convertible Preferred Stock

    [F1][F2]
    2026-06-05+9,4362,857,285 total
    From: 2026-06-05Common Stock (94,360 underlying)
Footnotes (4)
  • [F1]Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
  • [F2]The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
  • [F3]The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
  • [F4]On June 05, 2026, the 2025 Note was converted into 9,436 shares of Series D-1 Preferred Stock.
Signature
/s/ Edward Pershing|2026-06-05

Documents

1 file
  • 4
    ownership.xmlPrimary

    4